Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewProINDY is a DYRK1A/B inhibitor; prodrug form of INDY (Cat. No. 4997). Cell permeable. Inhibits phosphorylation of tau protein and rescues repressed calcineurin/NFAT signaling. Recovers Xenopus embryos from head malformation induced by DYRK1A overexpression in vivo.
分子量 | 277.34 |
公式 | C14H15NO3S |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 719277-30-2 |
PubChem ID | 68879595 |
InChI Key | RLEOCVDWLAYGRX-UHFFFAOYSA-N |
Smiles | O=C(C)/C=C1SC2=CC=C(OC(C)=O)C=C2N\1CC |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Ogawa et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat.Commun. 1 86 PMID: 20981014
关键词: ProINDY, ProINDY supplier, downs, syndrome-related, kinases, Dyrk1A/B, inhibitors, inhibits, tau, phosphorylation, hyperphosphorylation, calcineurin, NFAT, neural, stem, cells, DYRK, 4998, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 ProINDY 的部分引用包括:
Kim et al (2016) A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Dis Model Mech 9 839 PMID: 27483355
Seu et al (2015) Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. Sci Rep 89 6656 PMID: 25878110
目前没有该产品的评论。 Be the first to review ProINDY and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.